At the University of Cincinnati, a patient facing hospice after exhausting every conventional treatment for an aggressive pituitary tumor has achieved something medicine had never before recorded — complete remission, guided not by chance but by reading the tumor's own genetic code. By sequencing the cancer's DNA, researchers identified a specific mutation that made it vulnerable to immunotherapy, a class of drugs long proven in other cancers but never successfully deployed here. This case, now joined by three others worldwide, suggests that the long-standing assumption of pituitary cancer's i
First complete remission of aggressive pituitary cancer achieved via immunotherapy
Patient experienced vision loss and double vision from tumor progression before achieving complete remission through immunotherapy.
The cancer completely vanished and did not return after the medication was stopped.
Mark
Why did genomic testing make the difference here when standard treatments had already failed?
Mimi
Because the tumor's DNA told a story that imaging and pathology alone couldn't. Once they knew about the mismatch repair mutation, they could match the patient to a drug designed to exploit exactly that weakness. Standard chemotherapy is a sledgehammer. This was a key.
Mark
The patient was considering hospice. How much of a gamble was enrolling in an experimental trial at that point?
Mimi
It wasn't really a gamble in the traditional sense. The conventional path had closed. Hospice was the alternative. The trial offered a scientifically informed reason to believe this particular patient's tumor might respond. That's different from hope without evidence.
Mark
Three more patients worldwide have now achieved complete remission. Does that feel like a pattern or still too small a sample?
Mimi
It's enough to shift thinking. One case could be luck. Four cases with the same genetic signature responding the same way suggests mechanism. That's why Forbes is pushing so hard for genomic testing to become routine—because the next patient with that mutation shouldn't have to stumble into the right trial by accident.
Mark
What changes for a patient who gets this diagnosis tomorrow?
Mimi
Everything, potentially. If their tumor carries that mutation, immunotherapy becomes available now, not after surgery and radiation and chemotherapy have all failed. They might avoid years of suffering and ineffective treatment. That's the real shift.
Mark
The team is moving toward glioblastoma next. Why that tumor?
Mimi
Because it's even more aggressive and even more lethal than pituitary cancer. If this approach works there, the impact scales dramatically. Glioblastoma kills most patients within two years. If genomic testing and immunotherapy can change that trajectory, it matters enormously.
O Pulso
- A patient whose vision was stolen twice by a returning tumor was approaching hospice when their medical team chose to read the cancer's genome rather than reach for another blunt instrument.
- The discovery of a mismatch repair gene mutation transformed a terminal prognosis into an immunotherapy target — and the cancer disappeared completely, including the double vision it had caused.
- Three additional patients across the world have since achieved full remission using the same genomic-guided approach, establishing a pattern too consistent to dismiss as coincidence.
- Researchers are now pressing the global neurosurgical community to make tumor genomic testing standard practice, arguing that immunotherapy should be a first-line option for eligible patients — not a final, desperate one.
- The team's ambitions are already expanding toward glioblastoma, pairing immunotherapy with focused ultrasound technology designed to breach the blood-brain barrier and carry the treatment directly to the tumor.
At the University of Cincinnati, a patient facing hospice after exhausting every conventional treatment for an aggressive pituitary tumor has achieved something medicine had never before recorded — complete remission, guided not by chance but by reading the tumor's own genetic code. By sequencing the cancer's DNA, researchers identified a specific mutation that made it vulnerable to immunotherapy, a class of drugs long proven in other cancers but never successfully deployed here. This case, now joined by three others worldwide, suggests that the long-standing assumption of pituitary cancer's incurability was never a biological truth — only a failure of precision.
A patient arrived at the University of Cincinnati's Brain Tumor Center with blurring vision and left, after surgery, apparently cancer-free. The relief was short-lived. Within a year the tumor returned, chemotherapy failed to slow it, and double vision set in. With conventional options exhausted, the patient began contemplating hospice.
Neurosurgeon Jonathan Forbes and his team chose a different path. Rather than prescribing another broad-spectrum drug, they sequenced the tumor's DNA. The analysis revealed a mutation in the cancer's mismatch repair genes — a flaw that made it susceptible to immunotherapy, the same class of drugs that had transformed outcomes in melanoma and lung cancer but had never been successfully used against aggressive pituitary tumors. The patient enrolled in a matched clinical trial. The cancer vanished. The double vision cleared. When treatment stopped, the remission held.
Forbes and his colleagues published their findings in May 2026 in Surgical Neurology International, documenting the first confirmed complete remission of aggressive pituitary cancer through precision immunotherapy. Since then, three more patients worldwide with similar diagnoses have achieved the same outcome using the same strategy.
The underlying logic marks a genuine shift in oncological thinking. Traditional chemotherapy attacks any rapidly dividing cell indiscriminately. Immunotherapy works differently — it lifts the molecular camouflage that some tumors use to hide from the immune system, but only if the tumor carries the right genetic markers. That is why genomic testing is now central to Forbes's argument: without it, eligible patients will never know they could benefit.
He is calling on the global neuro-oncology community to make genomic testing standard for all aggressive pituitary tumors, and to offer immunotherapy as a first-line treatment rather than a last resort. The team is already planning ahead, designing a Phase 1 trial that will combine immunotherapy with focused ultrasound technology to help drugs cross the blood-brain barrier in glioblastoma patients — one of the deadliest brain cancers known. The message from Cincinnati is that the ceiling on what is treatable has moved.
A patient at the University of Cincinnati Gardner Neuroscience Institute's Brain Tumor Center walked into a doctor's office with blurring vision. What they found was a pituitary tumor—a growth at the base of the brain that, once removed surgically, seemed to have been vanquished. Vision returned. The pathology report, however, told a darker story: the tumor was biologically aggressive in ways that standard treatments rarely overcome.
For about a year, the patient remained cancer-free. Then the tumor came back. Chemotherapy with temozolomide, the conventional next step for such cases, failed to slow it. The cancer advanced. Vision deteriorated again, this time into double vision. The patient was running out of options and began considering hospice care.
What happened next marks a turning point in how doctors treat one of the rarest and most lethal brain cancers. Jonathan Forbes, an associate professor of neurosurgery at the University of Cincinnati, and his team took a different approach. Instead of reaching for another broad-spectrum drug, they sequenced the tumor's DNA. That genetic analysis revealed something crucial: the cancer carried a specific mutation in its mismatch repair genes—a defect that made it vulnerable to immunotherapy, a class of drugs that had revolutionized treatment for melanoma and lung cancer but had never been successfully deployed against aggressive pituitary tumors.
The patient enrolled in a clinical trial matched to that genetic profile. The results were unprecedented. The cancer vanished completely. The double vision resolved. When the immunotherapy was stopped, the cancer did not return. Forbes and his colleagues published their findings in May 2026 in Surgical Neurology International, documenting the first confirmed complete remission of an aggressive pituitary cancer achieved through this precision-medicine approach.
Since that initial case, three additional patients worldwide with similar aggressive pituitary tumors or pituitary carcinomas have achieved complete remission using the same strategy. The pattern is clear enough that Forbes is now urging the global neurosurgical and neuro-oncology communities to make tumor genomic testing standard practice for all pituitary carcinomas and aggressive pituitary adenomas. The logic is straightforward: if a tumor carries the right genetic signature, immunotherapy should be offered as a first-line treatment, not a last resort.
The shift represents a fundamental change in how oncologists think about brain tumors. Traditional chemotherapy like temozolomide works indiscriminately, targeting any rapidly dividing cell. Immunotherapy, by contrast, is precise. Some cancer cells evolve to produce proteins that suppress the immune system, essentially hiding from the body's natural defenses. Immunotherapy blocks those proteins, allowing the immune system to recognize and attack the tumor as it should. But this only works if the tumor carries the mutations that trigger this vulnerability—which is why genomic testing matters.
Forbes emphasized that pituitary tumors themselves are common, but the aggressive variants are rare and historically have resisted standard treatments. Surgery, radiation, and chemotherapy have all proven inadequate for the most dangerous cases. Immunotherapy changes that calculus, at least for patients whose tumors carry the right genetic markers. He is calling for immediate expanded access to these drugs for eligible patients, arguing that the infrastructure and expertise exist to identify who should receive them.
The team is already planning the next phase. They intend to apply the same genomic-testing-plus-immunotherapy strategy to glioblastoma, one of the deadliest brain tumors. A planned Phase 1 trial will pair immunotherapy with navigated focused ultrasound technology designed to help the drugs cross the blood-brain barrier and reach the tumor, amplifying the immune system's ability to kill cancer cells. For patients with aggressive brain tumors that have exhausted conventional options, the message from Cincinnati is clear: the rules are changing.
Citações Notáveis
Using that scientifically-informed regimen, he was able to clear the cancer. The double vision completely resolved on the immunotherapy regimen.— Jonathan Forbes, MD, University of Cincinnati
Providers across the country and the world need to know to look for the mutations. If the tumor DNA fits a particular profile, patients should be permitted to have expanded access to these potentially life-saving medications immediately.— Jonathan Forbes, MD
Quer a matéria completa?
Leia o original em Medical Xpress ↗
Health & Medicine